secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001628280-24-010791
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience reports FY2023 revenue $24.4M (+60% YoY); net loss $65.8M
-------------------------------------------------------------------------

- FYARRO net sales $24.4M for FY2023, up 60% YoY; Q4 sales $6.3M (+21% YoY).
- Net loss $65.8M for FY2023 vs $60.5M in 2022; cash $108.8M funding into Q4 2025.
- PRECISION1 trial enrollment on track to complete by May 2024; two-thirds interim analysis expected Q3 2024.
- Phase 2 trials in accelerated endometrial cancer (EEC) and neuroendocrine tumors (NETs) actively enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/aadi-20240313.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-010791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer